drugset
drugset / Trial / NCT03873415

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

NCT03873415 ↗

Phase 1 Completed 9 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males

Timeline

Start
2019-01-25
Primary completion
2019-05-01
Completion
2019-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — Oral

Indications

psoriasis